Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hVPS34 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal, Parenteral
01
Overview
hVPS34 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the human vacuolar protein sorting 34 (hVPS34) gene, also known as PIK3C3. hVPS34 is a class III phosphoinositide 3-kinase (PI3K) that plays a critical role in the initiation of autophagy by producing phosphatidylinositol 3-phosphate (PI3P), which is essential for autophagosome formation. In research settings, such as the study of pancreatic cancer (PaCa) cells, hVPS34 siRNA is used to investigate the dependency of autophagic pathways on the canonical Beclin-1/hVPS34 complex. While hVPS34 is typically a key mediator of autophagy, some studies have indicated that certain cancer cells may utilize non-canonical, hVPS34-independent pathways for survival under stress conditions like hypoxia or nutrient deprivation.
- Other names
- PIK3C3 siRNAPIK-3C3 siRNAPIK 3C3 siRNAhuman VPS34 siRNAvps34 siRNAvps-34 siRNAvps 34 siRNA
02
Targets
PIK3C3 (PI3K class III)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on hVPS34 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hVPS34 siRNA.